HELEN M. THACKRAY, M.D.

Corporate Board Profile

Tech Score: 0/100

BIOCRYST PHARMACEUTICALS INC

Filing Date	Source Excerpt
2020-03-31	Helen M. Thackray was appointed to the Board in September 2019. Dr. Thackray is currently Chief Medical Officer and Senior Vice President of clinical development at GlycoMimetics, Inc., a publicly traded oncology-focused biotechnology company. ... 2019 DIRECTOR COMPENSATION ... The following table provides information related to the compensation of our non-employee directors during fiscal 2019. ... Helen M. Thackray, M.D 18,333 76,968 – – 95,301 ... Dr. Thackray was appointed to the Board of Directors on September 20, 2019 and received an option to purchase 40,000 shares in accordance with the automatic option grant program under our Stock Incentive Plan.

Filing Date

Source Excerpt

2020-03-31

Helen M. Thackray was appointed to the Board in September 2019. Dr. Thackray is currently Chief Medical Officer and Senior Vice President of clinical development at GlycoMimetics, Inc., a publicly traded oncology-focused biotechnology company. ... 2019 DIRECTOR COMPENSATION ... The following table provides information related to the compensation of our non-employee directors during fiscal 2019. ... Helen M. Thackray, M.D 18,333 76,968 – – 95,301 ... Dr. Thackray was appointed to the Board of Directors on September 20, 2019 and received an option to purchase 40,000 shares in accordance with the automatic option grant program under our Stock Incentive Plan.

Data sourced from SEC filings. Last updated: 2026-02-03